Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth
Amphastar is shifting away from commoditized generics toward higher‑value proprietary products, targeting a 50% proprietary mix by 2026 and maintaining roughly $60–$75M annual R&D while pursuing ...
When you are building an infill home in the inner city, you should be aware of the requirements needed for overhead services like electrical, metering equipment and overhead conductors. Here’s an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results